Phase III trials demonstrate promise for new oral treatments

被引：0

|

作者：

不详

机构：

来源：

PROGRESS IN NEUROLOGY AND PSYCHIATRY | 2010年 / 14卷 / 02期

关键词：

D O I：

暂无

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

引用

收藏

页码：33 / 33

页数：1

相关论文

共 50 条

[1] Oral Solo Phase III results demonstrate promise for tasocitinib for treatment of rheumatoid arthritis
不详
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (01) : 6 - 6
[2] Targeted inhibition of coagulation: oral agents show promise in phase III trials
Bauer, K. A.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) : 2175 - 2177
[3] New diabetes drug lixisenatide shows promise in Phase III clinical trials
不详
[J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (06) : 797 - 797
[4] New HIV-1 prodrug shows promise in phase III trials
Louise Stone
[J]. Nature Reviews Urology, 2015, 12 (6) : 301 - 301
[5] Phase III promise for oral multiple sclerosis therapy
[J]. Nature Reviews Drug Discovery, 2009, 8 : 98 - 98
[6] TRIAL WATCH Phase III promise for oral multiple sclerosis therapy
不详
[J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (02) : 98 - 98
[7] Editorial: The promise of risk-based allocation trials in assessing new treatments
Mosteller, F
[J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (05) : 622 - 623
[8] Investigating the impact of phase II trial design parameters on the ability to successfully screen new treatments for phase III trials
Elbeltagi, Nada
Brown, Sarah
Stallard, Nigel
Brown, Julia
Gregory, Walter
Collinson, Fiona
[J]. TRIALS, 2017, 18
[9] Oral treatments for diabetic neuropathy struggle to demonstrate clinical efficacy
不详
[J]. DIABETES OBESITY & METABOLISM, 1999, 1 (04): : 250 - 250
[10] Results of phase II and phase III trials with new aromatase inhibitors
Jonat, W
[J]. BREAST, 1996, 5 (03): : 209 - 215

← 1 2 3 4 5 →